anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In recent years, the incidence of tibial plateau fractures (TPF) has been on the rise. Deep vein thrombosis (DVT) may lead to poor prognosis in patients. The systemic immune-inflammation index(SII) are novel biomarkers of inflammation, and this study aims to verify their predictive effect and construct the nomogram model. This study used binary logistic regression analysis to predict the predictive effect of SII on the occurrence of DVT in tibial plateau fracture patients. And use R studio to construct nomogram model. The results showed that Age (1.03 [1, 1.06], p = 0.032), SII (3.57 [1.68, 7.61], p = 0.04), and NC (7.22 [3.21, 16.26], p < 0.001) were independent predictive factors for DVT. The nomogram demonstrated good predictive performance with small errors in both the training and validation groups, and most clinical patients could benefit from them. The nomogram constructed based on SII can assist clinicians in early assessment of the probability of DVT occurrence.
Particular care is needed for patients who are transferred from systemically active corticosteroids to DULERA because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although DULERA may improve control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity necessary for coping with these emergencies.

During periods of stress or severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a medical identification card indicating that they may need supplementary systemic corticosteroids during periods of stress or severe asthma attack.

Patients requiring systemic corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to DULERA. Lung function (FEV1 or PEF), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of systemic corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to DULERA may unmask allergic conditions previously suppressed by the systemic corticosteroid therapy, e.g., rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions.

During withdrawal from oral corticosteroids, some patients may experience symptoms of systemically active corticosteroid withdrawal, e.g., joint and/or muscular pain, lassitude, and depression, despite maintenance or even improvement of respiratory function.
In recent decades, the prevalence of thyroid cancer has risen substantially, with papillary thyroid microcarcinoma (PTMC) constituting over 50% of cases. Although most PTMCs exhibit indolent growth and a favorable prognosis, some present an increased risk of recurrence and an unfavorable prognosis due to high-risk characteristics such as lymph node metastasis, extrathyroidal extension, and distant metastasis. The early identification of clinically progressing PTMC remains elusive. In this review, the authors summarize findings from PTMC progression-related literature, highlighting that factors such as larger tumor size, cervical lymph node metastasis, extrathyroidal extension, younger age, higher preoperative serum thyroid-stimulating hormone levels, family history, and obesity positively correlate with PTMC progression. The role of multifocality in promoting PTMC progression; however, remains contentious. Furthermore, recent studies have shed light on the impact of mutations, such as BRAF and TERT mutations, on PTMC progression. Researchers have identified several mRNAs, noncoding RNAs, and proteins associated with various features of PTMC progression. Some studies propose that peripheral and tumor tissue-infiltrating immune cells could serve as biomarkers for the clinical progression of PTMC. Collectively, these clinical and molecular features offer a rationale for the early detection and the development of precision theranostic strategies of clinically progressive PTMC.
Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
Argatroban in Sodium Chloride Injection is supplied as a single-dose vial containing 50 mg argatroban in 50 mL of aqueous sodium chloride solution (1 mg/mL). The vial is sealed with a gray rubber stopper and a green aluminum flip-off seal.

NDC 16729-430-11 – Package containing one vial of Argatroban in Sodium Chloride injection (each vial contains 50 mg of argatroban).

NDC 16729-430-43 – Package containing 10 vials of Argatroban in Sodium Chloride injection (each vial contains 50 mg of argatroban).

Storage

Store the vials in original cartons at 20ºC to 25ºC (68ºF to 77°F) [see USP Controlled Room Temperature]: excursion permitted between 15°C to 30°C (59°F to 86°F). Do not refrigerate or freeze. Protect from light and store in carton. Do not use if solution is cloudy or contains a precipitate.
A computerized checklist system for use in the medical field preferably comprises a checklist unit adapted to be held in an operator's hand and a cradle for supporting the checklist unit. Each of these components includes a microprocessor for controlling the operation thereof. An optical link is provided to transmit data between the devices. The checklist unit includes suitable memory for storing alphanumeric checklist data including a sequence of checklist items. A display and a voice synthesizer selectively output checklist items. The checklist unit includes a keypad having a plurality of control switches for enabling an operator of the checklist unit to enter one of a plurality of signals indicating that the operator has taken one of a plurality of predetermined actions in response to each checklist item outputted by on the display and/or spoken by the voice synthesizer. The handheld unit also includes a program, responsive to processing of the checklist items during a work session, for storing a session log, the session log including data identifying each checklist item outputted during the work session, the signal entered by the operator in response to each checklist item, and a time when such signal was entered by the operator. Following placement of the handheld unit in the cradle after the work session, the session log data is downloaded to the cradle and then printed in a predetermined format.
BACKGROUND AND AIM: COPD nursing plays a crucial role in alleviating disease symptoms, prolonging patient survival, and is therefore of paramount importance. However, authoritative research findings, research hotspots, and development trends in the field of COPD are still unclear. This study aimed to examine authoritative research findings, research hotspots, and trends in the field of COPD nursing. Descriptive statistics and bibliometric and visual analyses of the literature were conducted.
METHODS: Bibliometric data were obtained from the Web of Science database. Citespace was used to explore publication trends, countries, institutions, journals, authors, keywords, and co-citation characteristics of the included literature in order to summarize the key research in the field of COPD nursing.
RESULTS: In total, 693 articles on COPD nursing were published. 1998-2014 showed a rapid growth period in this research field, which stabilized in 2015-2022. The research content could mostly be summarized into five categories: acute exacerbation, quality of life, risk, evidence-based nursing, and pulmonary rehabilitation. The research hotspots in 1998-2014 included randomized controlled trials, education, elderly patients, nursing home residents, nursing homes, rehabilitation, and prevalence. Research in 2015-2022 focused on impact, palliative care, needs, and predictors. In recent years, research mainly concentrated on symptom management models, cost-effectiveness, and cumulative meta-analysis.
CONCLUSION: Bibliometric analysis of COPD nursing articles indicates that the focus of COPD nursing research is shifting from tertiary prevention to primary and secondary prevention. Helping patients achieve self-management of symptoms, reducing the financial burden of COPD on healthcare, and summarizing research evidence by meta-analyses will likely remain the focus of future research.
A mobile and adaptable fitness system allows a fitness device to be used to control an application running on a host device. The system includes one or more controllers, a motion sensing device, and a host device. The hand controllers may be mounted on the handlebars of the fitness device or held in a user's hands and include buttons that the user can press. The motion sensing device may be mounted on the user or on a moving part of the fitness device and contains sensors that capture motion performed by the user. The host device receives input data from the hand controllers and the motion sensing device and generates an activity vector representing the intensity at which the user performs a fitness activity. Based on the activity vector, the host device controls an object in an application, such as a character, based on the input data.
BACKGROUND: Infected pancreatic necrosis (IPN) is a severe complication of acute pancreatitis, with mortality rates ranging from 15 to 35%. However, limited studies exist to predict the survival of IPN patients and nomogram has never been built. This study aimed to identify predictors of mortality, estimate conditional survival (CS), and develop a CS nomogram and logistic regression nomogram for real-time prediction of survival in IPN patients.
METHODS: A prospective cohort study was performed in 335 IPN patients consecutively enrolled at a large Chinese tertiary hospital from January 2011 to December 2022. The random survival forest method was first employed to identify the most significant predictors and capture clinically relevant nonlinear threshold effects. Instantaneous death risk and CS was first utilized to reveal the dynamic changes in the survival of IPN patients. A Cox model-based nomogram incorporating CS and a logistic regression-based nomogram were first developed and internally validated with a bootstrap method.
RESULTS: The random survival forest model identified seven foremost predictors of mortality, including the number of organ failures, duration of organ failure, age, time from onset to first intervention, hemorrhage, bloodstream infection, and severity classification. Duration of organ failure and time from onset to first intervention showed distinct thresholds and nonlinear relationships with mortality. Instantaneous death risk reduced progressively within the first 30 days, and CS analysis indicated gradual improvement in real-time survival since diagnosis, with 90-day survival rates gradually increasing from 0.778 to 0.838, 0.881, 0.974, and 0.992 after surviving 15, 30, 45, 60, and 75 days, respectively. After further variables selection using step regression, five predictors (age, number of organ failures, hemorrhage, time from onset to first intervention, and bloodstream infection) were utilized to construct both the CS nomogram and logistic regression nomogram, both of which demonstrated excellent performance with 1000 bootstrap.
CONCLUSION: Number of organ failures, duration of organ failure, age, time from onset to first intervention, hemorrhage, bloodstream infection, and severity classification were the most crucial predictors of mortality of IPN patients. The CS nomogram and logistic regression nomogram constructed by these predictors could help clinicians to predict real-time survival and optimize clinical decisions.
Antibodies that specifically bind the extracellular domain of IRT A3 immunoglobulin superfamily receptor translocation associated or that specifically bind the extracellular domain of IRTA5 are disclosed herein. Antibodies ' that specifically bind to IRT A3 do not specifically bind IRTAl, IRT A2, IRTA4, IRTA5, or IRTA6. Antibodies that specifically bind to IRTA5 do not specifically bind IRTAl, IRTA2, IRTA3, IRTA4, or IRTA6. The antibodies can be conjugated to effector molecules, including detectable labels, radionucleotides, toxins and chemotherapeutic agents. Nucleic acid molecules encoding these antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. Methods also are provided for detecting IRTA5 or for detecting IRT A3, as well as methods for treating various B cell malignancies. Methods are disclosed for assessing the efficacy of a therapy for an autoimmune disease.
A disclosed method for assessing and influencing behavior, including workplace activity, of a personal computer user. User behavior and/or activity information pertaining to the user is received from the user's various smart devices such as a laptop, desktop, or hybrid computer, a mobile device, and a wearable device. The user's information is collected and an intelligence resource learns norms and distributions for various parameters and defines one or more user behavior thresholds. The user's present condition may be evaluated based on recently observed and collected activity and a risk factor score may be assigned. An initial behavior-influencing action appropriate for the user condition and risk level is performed. Disclosed methods further include performing at least one extended action pertaining to the initial action. The extended action can include evaluating and effectiveness of the initial action or the performance of a progressive action or a supplementary action.
Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
The invention relates to substance and method for treating neoplasms in mammals. A substance for treating neoplasm comprises water comprising from 99.76 to 99.99 molecular % of light isotopologue  1 H 2   16 O and up to 100% of residual isotopologues. A method for treating neoplasm comprises a step of administering to a mammal in need thereof an effective amount of water comprising from about 99.76 to about 99.99 molecular % of light isotopologue  1 H 2   16 O and up to 100% of residual isotopologues. Preferably, the effective amount of the water comprising from about 99.76 to about 99.99 molecular % of light isotopologue  1 H 2   16 O and up to 100% of residual isotopologues is administered orally or parenterally. Preferably, the method further comprises a step of administering to a mammal in need thereof from is 0.1 to 50 mg per kg body weight of succinic acid or a pharmaceutically acceptable salt thereof orally or parenterally. The method may further comprise a step of administering to a mammal in need thereof an effective amount of an anti-neoplasm agent. Preferably, the mammal is a human.
The present invention provides a method of treating pancreatitis comprising administering to a human in need thereof an effective amount of hemin. The administration of hemin is preferably parenteral. In another aspect, the present invention provides a method of pancreatitis prophylaxis comprising administering to a human in need thereof an effective amount of hemin. In a still further aspect, the present invention contemplates a method of inducing an HO gene comprising administering to a human in need thereof an HO-inducing effective amount of hemin. Preferably, the HO gene is the HO-I gene. In a still further aspect, the present invention contemplates a method of inducing an HO gene in leukocytes for recruitment to the pancreas to treat pancreatitis comprising administering to a human in need thereof an HO-inducing effective amount of hemin. In another embodiment, the present invention contemplates a method of inducing an HO gene in leukocytes for recruitment to the pancreas for prophylaxis of pancreatitis comprising administering to a human in need thereof an HO-inducing effective amount of hemin. In a yet further aspect, the present invention provides a method of ex vivo treatment of pancreatitis comprising providing peripheral blood leukocytes, followed by contact with hemin to form induced peripheral blood leukocytes then infusing the induced peripheral blood leukocytes into a human in need thereof.
FIELD: pharmacy. SUBSTANCE: invention relates to a solid pharmaceutical dosing form that provides the slow release of drug. The form is obtained by direct pressing cross-linked amylose of different cross-linking degree, α--amylase and a pharmaceutical agent. Cross-linked amylose ensures to provide the gradual drug release and α--amylase ensures to modulate time of release. Amount of α--amylase is 100 or less enzymatic units. EFFECT: improved quality and properties of the form. 5 cl, 5 dwg, 5 ex
Postoperative pain after thoracic surgery which is attributed to muscle incision, rib retraction, and intercostal nerve damage may be severe such a degree that it may cause pulmonary complications such as atelectasis, pneumonia and increased oxygen consumption. Because video assisted thoracic surgery (VATS) has some advantages over open thoracotomy such as reduced pain, shoulder dysfunction, early pulmonary impairment, rapid recovery, short hospital stay and low complication risk, it has recently been evaluated as the standard surgical procedure for lung surgery. Although VATS is a less painful procedure than open thoracotomy, patients may still feel severe pain during the first hours at postoperative period. As thoracic epidural analgesia (TEA) is the gold standard analgesic technique after thoracotomy, it is also being used for analgesia management following VATS. Hence TEA has some difficulties in administration and side effects, minimally invasive analgesic techniques are supported for pain management in patients who underwent VATS. The gold standard minimal invasive analgesic technique for VATS is still be questioned. Thoracic paravertebral block (TPVB) has been evaluated as the first step regional analgesia technique after VATS. However, its administration is difficult because of its anatomical proximity to important structures such as the pleura and central neuro-axial system. Therefore it may cause complications such as pneumothorax and neuro-axial injury. The ultrasound (US) guided erector spina plane block (ESPB) - a novel interfacial plan block defined by Forero et al. in 2016 - has the advantage of being away from the pleural and neurological structures, thus the risk of complications is lower. In the literature, case reports about the analgesic effect of ESPB after thoracotomy and VATS has been increasing. However there is no randomized study for VATS yet. In this study, investigators aimed to evaluate the efficacy of US-guided ESPB for postoperative analgesia management following VATS.
Patients receive p97 inhibitor CB-5339 tosylate PO QD 4 days on and 3 days off. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
The experimental arm is a 1-2 mins motion-sensoring video game, which can accommodate 1-4 individuals, engaging their entire bodies in the physical motions involved. It aims to increase PA intention by increasing their motivation, as well as personal and family well-being by increasing the interaction with family members. Assessments will be conducted at two different time points, immediately following the intervention (T2) and after 1-month follow-up (T3).
Heavy metal salts of hyaluronic acid have been prepared. In particular, this invention is directed to silver, gold, cerium and tungsten salts of hyaluronic acid. These heavy metal salts of hyaluronic acid are useful as antimicrobial agents. Gold hyaluronate may also be used to treat arthritis. This invention also concerns methods of making the silver salt of hyaluronic acid as well as compositions containing silver hyaluronate or gold hyaluronate. The invention also concerns composition containing heavy metal salts having radioactively labelled hyaluronate moieties.
In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
Doxycycline Capsules USP is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Doxycycline 150 mg, 100 mg and 50 mg capsules contain doxycycline monohydrate equivalent to 150 mg, 100 mg or 50 mg of doxycycline for oral administration. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline. 

Structural formula:

C22H24N2O8•H2O M.W. = 462.45

Doxycycline Capsules USP has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. 

Inactive ingredients include colloidal silicon dioxide, gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and titanium dioxide. In addition, the 50 mg strength contains FD&C Yellow #6 and D&C Yellow #10. The 100 mg strength also contains black iron oxide, red iron oxide and yellow iron oxide. The 150 mg strength includes FD&C Red #40 and FD&C Yellow #6.